Many studies have documented that SF3B1 mutations play an essential role in the onset and progression stages of MDS, regulating pathophysiological processes including disorders of erythropoiesis, dysregulation of iron metabolism homeostasis, hyperinflammatory and R-loop accumulation. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.